Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Feb;25(2):207-12.
doi: 10.1089/aid.2008.0191.

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

Nancie M Archin  1 , Amy Espeseth, Daniel Parker, Manzoor Cheema, Daria Hazuda, David M Margolis
Affiliations
Case Reports

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

Nancie M Archin et al. AIDS Res Hum Retroviruses. 2009 Feb.

Abstract

Histone deacetylases (HDACs) act on histones within the nucleosome-bound promoter of human immunodeficiency virus type 1 (HIV-1) to maintain proviral latency. HDAC inhibition leads to promoter expression and the escape of HIV from latency. We evaluated the ability of the potent inhibitor recently licensed for use in oncology, suberoylanilide hydroxamic acid (SAHA; Vorinostat), selective for Class I HDACs, to induce HIV promoter expression in cell lines and virus production from the resting CD4(+) T cells of antiretroviral-treated, aviremic HIV-infected patients. In J89, a Jurkat T cell line infected with a single HIV genome encoding the enhanced green fluorescence protein (EGFP) within the HIV genome, SAHA induced changes at nucleosome 1 of the HIV promoter in chromatin immunoprecipitation (ChIP) assays in concert with EGFP expression. In the resting CD4(+) T cells of antiretroviral-treated, aviremic HIV-infected patients clinically achievable exposures to SAHA induced virus outgrowth ex vivo. These results suggest that potent, selective HDAC inhibitors may allow improved targeting of persistent proviral HIV infection, and define parameters for in vivo studies using SAHA.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Like VPA, SAHA increases acetylation of Nuc 1 and decreases HDAC-1 occupancy at the HIV-1 LTR. J89 cell treated with media, 3 mM VPA, or 500 nM SAHA for 4 h were assayed by chromatin immunoprecipitation with anti-acetylated H3, anti-HDAC-1. To demonstrate that the apparent quantitative changes are significant in this semi-quantitative assay, DNA products of ChIP were quantitated in triplicate by real-time PCR. Assays are representative of 3 independent experiments, and real-time quantitation of the fold change relative to untreated control is shown.
FIG. 2.
FIG. 2.
SAHA activates HIV LTR transcription. J89 cells were treated with the indicated concentrations of SAHA or VPA for 4hrs. Semi-quantitative RT PCR was performed on total RNA isolated from treated and untreated cells as described in methods. The data presented is the mean ± SE of 3 independent experiments.
FIG. 3.
FIG. 3.
Toxicity of SAHA in seronegative donor PBMC and J89 cells. PBMC or J89 cells were cultured in the absence or presence of SAHA or VPA at the indicated concentrations. MTT assays were performed as described in methods. The percentage of proliferating cells was calculated compared to cells cultured in standard media. The data represent the mean ± SE of 3 independent experiments.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wong JK. Hezareh M. Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291–1295. - PubMed
    1. Finzi D. Hermankova M. Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300. - PubMed
    1. Chun TW. Stuyver L. Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193–13197. - PMC - PubMed
    1. Pazin MJ. Sheridan PL. Cannon K, et al. NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev. 1996;10:37–49. - PubMed
    1. Van Lint C. Emiliani S. Ott M. Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 1996;15:1112–1120. - PMC - PubMed

Publication types

LinkOut - more resources